Nuvectra Corporation is in the medical devices industry and is part of the healthcare sector. The company CEO is Fred B. Parks. Nuvectra Corp is a medical device company in the United States. It manufactures devices to address chronic neurological disorders. The company has two reportable segments namely Nuvectra and NeuroNexus.

Previous Intraday Performance:

The NVTR shares had a previous change of 1.21% which opened at 12.45 and closed at 12.54. It moved to an intraday high of 12.65 and a low of 12.20.

SeekingAlpha:  Nuvectra Corporation (NVTR) Investor Presentation – Slideshow

Historical Performance:

Over the last five trading days, NVTR shares returned 4.07% and in the past 30 trading days it returned -11.57%. Over three months, it changed -29.75%. In one year it has changed 6.81% and within that year its 52-week high was 25.17 and its 52-week low was 11.26. NVTR stock is 11.37% above its 52 Week Low.

Our calculations result in a 200 day moving average of 18.02 and a 50 day moving average of 13.90. Right now, NVTR stock is trading -30.40% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Nuvectra Corporation (NVTR) Investor Presentation – Slideshow


The company has a market cap of $222.0m with 17.7m shares outstanding and a float of 17.1m shares. Trading volume was 119,063 shares and has experienced an average volume of 273,445 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Nuvectra Corporation was -3.19 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.80.

Below was the last reported quarterly earnings per share:
12-31-2018:  -0.65
09-30-2018:  -0.87
06-30-2018:  -0.83
03-31-2018:  -0.84

The next earnings report will be: 03-20-2019

EPS growth is an important number as it indicates the future prospects of Nuvectra Corporation; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 9.60% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 114.30% of institutional ownership.

I calculated the beta to be 0.01

Business Wire:  Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -69.25%, return on assets is -39.26%, profit margin is -93.08%, price-to-sales is 4.18 and price-to-book is 2.36.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here